Darunavir/cobicistat

Darunavir/cobicistat, sold under the brand names Prezcobix (US) and Rezolsta (EU), is an antiretroviral medication used to treat and prevent HIV/AIDS.[1] It is a fixed dose combination drug containing 800 mg of darunavir and 150 mg of cobicistat.[1][2][3][1] Darunavir is an HIV protease inhibitor and cobicistat increases the effectiveness of darunavir by blocking its metabolism by the enzyme CYP3A.[3][1]

Kombinasi
Darunavir HIV protease inhibitor
Cobicistat Cytochrome P450 (CYP3A) inhibitor
Data klinis
Jeneng dagang Rezolsta, Prezcobix
AHFS/Drugs.com Professional Drug Facts
Data lisènsi US Daily Med:link
Kat. kehamilan B2(AU) ?(US)
Status hukum -only (US)
Rute By mouth
Pangenal
Nomor CAS 206361-99-1 ☒N
Kode ATC J05AR14
PubChem CID 57327017
UNII YO603Y8113Cithakan:Fdacite
KEGG D10832

Darunavir/cobicistat was approved for use in the European Union in November 2014, and for use in the United States in January 2015.[4][5][6][1][7]

Rujukan

besut
  1. a b c d e "Prezcobix- darunavir ethanolate and cobicistat tablet, film coated". DailyMed. 6 June 2019. Dibukak ing 20 February 2020.
  2. "Darunavir / Cobicistat". AIDSinfo. U.S. Department of Health and Human Services. Diarsip saka sing asli ing 2020-03-03. Dibukak ing 2020-03-26.
  3. a b "Darunavir and Cobicistat (Professional Patient Advice)". Drugs.com. 16 September 2019. Dibukak ing 19 February 2020.
  4. "Rezolsta EPAR". European Medicines Agency (EMA). Dibukak ing 4 April 2020.
  5. "Antiretroviral drugs used in the treatment of HIV infection". U.S. Food and Drug Administration (FDA). 12 April 2018. Dibukak ing 19 February 2020.
  6. "Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA". Medscape. January 30, 2015.
  7. "Prezcobix (darunavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 June 2016. Dibukak ing 4 April 2020.

Pranala jaba

besut

Cithakan:HIVpharm